The Results From a Phase II Study Analyzing First-Line Eribulin Mesylate

Clinical Pearls

Kristi McIntyre, MD, a physician with Texas Oncology, discusses the results of a phase II, multicenter, single-arm study looking at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.

• Overall response rate was 29%
• Clinical benefit rate (CR, PR and stable disease) was 52%
• Eribulin does not have hypersensitivity reactions like taxanes
• The study contained both triple-negative and hormone receptor-positive patients
• All metastatic breast cancer patients were HER2-negative